Old malaria drug could boost lung cancer treatment
NCT ID NCT04648033
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested adding the anti-parasitic drug atovaquone to standard chemotherapy and radiation for people with locally advanced non-small cell lung cancer. The main goal was to find the safest dose of atovaquone in this combination. Twenty-one participants received one of four doses to check for severe side effects. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atovaquone (an anti-parasitic drug) combined with standard chemotherapy (cisplatin and vinorelbine) and radiation therapy
- What this could lead to
- If it works, this could point toward a way to make standard lung cancer treatment more effective by targeting low-oxygen areas in tumors.
- What could go wrong
- This is a very early, small phase 1 trial with only 21 people, focused on safety and dosing. It is not designed to prove the combination works, and side effects may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Churchill Hospital, Oxford University Hospitals
Oxford, OX3 7LE, United Kingdom
-
Guy's and St Thomas'
London, SE1 9RT, United Kingdom
-
Western General Hospital, NHS Lothian
Edinburgh, EH4 2XU, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a PET scan reveal hidden heart harm from lung cancer treatment?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Can a new drug shrink Hard-to-Treat tumors?
- Could an asthma drug help fight lung cancer? early trial investigates
- New combo therapy aims to boost lung cancer survival
- Radiation 'Priming' could make lung cancer treatment more effective